Triple negative breast cancer (TNBC) is characterized by the clinical absence of ER, PgR and HER2 diagnosed mainly via immunohistochemistry and accounts for 10–20% of all breast cancer [4]. This evidence concerns the gene ESR1 and breast cancer.